| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
3-Pyridinemethanol targets cholesterol metabolism pathways as a cholesterol-lowering agent. It can be selectively oxidized to vitamin B3, which plays a role in lipid metabolism. The compound acts as a direct-acting peripheral vasodilator, causing vasodilation and decreasing blood pressure. It is an alcohol analog of nicotinic acid. The compound's mechanism involves affecting cholesterol metabolism to lower blood cholesterol levels. As a pyridine derivative, it may interact with enzymes involved in oxidation-reduction reactions. Its vasodilatory effects suggest interactions with vascular smooth muscle targets.
|
|---|---|
| ln Vitro |
In vitro studies have demonstrated that 3-Pyridinemethanol acts as a cholesterol-lowering agent. The compound can be selectively oxidized to vitamin B3 in vitro. As a direct-acting peripheral vasodilator, it causes vasodilation in vascular tissues. The compound's effects on lipid metabolism have been characterized in various in vitro systems. Its role as a vasodilator agent and antilipemic drug has been documented. These in vitro findings support its potential applications in cardiovascular disease research and lipid metabolism studies. The compound is used as an analytical standard for research and analytical applications.
|
| ln Vivo |
In vivo studies have demonstrated that 3-Pyridinemethanol acts as a peripheral vasodilator, causing flushing and potentially decreasing blood pressure. Its cholesterol-lowering effects have been documented. The compound can be oxidized to vitamin B3 in vivo, contributing to its lipid metabolism effects. Its role as a vasodilator agent and antilipemic drug has been established. The compound may be useful for cardiovascular disease prevention and treatment. Further research is needed to fully characterize its in vivo pharmacokinetic and pharmacodynamic properties and to evaluate its therapeutic potential in cardiovascular diseases.
|
| Enzyme Assay |
In vitro enzyme assays for 3-Pyridinemethanol typically involve testing its oxidation to vitamin B3. Enzyme activity is measured by monitoring the conversion of the compound to nicotinic acid using spectrophotometric or chromatographic methods. For cholesterol-lowering activity, enzyme assays measuring HMG-CoA reductase activity or lipid metabolism enzymes are performed. For vasodilatory activity, vascular smooth muscle contraction assays are performed using tissue baths. The compound's purity and identity are assessed using analytical chemistry methods such as nuclear magnetic resonance spectroscopy and mass spectrometry. All assays are performed with appropriate controls and standardized protocols.
|
| Cell Assay |
In vitro cell-based assays for 3-Pyridinemethanol involve culturing hepatocytes or other relevant cell lines to evaluate its cholesterol-lowering effects. Cells are treated with varying concentrations of the compound and lipid metabolism is assessed by measuring cholesterol synthesis or uptake. For vasodilatory studies, vascular smooth muscle cells are treated and relaxation responses are measured. Cell viability is assessed using MTT or similar colorimetric assays. The compound's effects on gene expression related to lipid metabolism are evaluated by quantitative PCR. All experiments are performed in triplicate with appropriate controls to ensure statistical reliability.
|
| Animal Protocol |
In vivo animal experiments for 3-Pyridinemethanol utilize rodent models to evaluate its cholesterol-lowering and vasodilatory effects. Animals are administered the compound orally or intravenously. For cholesterol-lowering studies, blood lipid levels are measured over time. For vasodilatory studies, blood pressure is monitored. Parameters assessed include total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides, blood pressure, and heart rate. At study termination, blood and tissue samples are collected for biochemical analysis and histopathological examination. Control groups receiving vehicle alone are included for comparison. All procedures comply with institutional animal care and use committee guidelines.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of 3-Pyridinemethanol reflect its nature as a small pyridine compound. It has a molecular weight of 109.13 and the molecular formula C6H7NO. The compound has a purity of 99.53%. As a small hydrophilic molecule, it is readily absorbed through the gastrointestinal tract. The compound is distributed throughout the body and metabolized in the liver. It can be selectively oxidized to vitamin B3. The compound's vasodilatory effects suggest rapid onset of action. Complete pharmacokinetic profiling including half-life, clearance, and bioavailability would require further systematic studies using appropriate analytical methods such as high-performance liquid chromatography-mass spectrometry.
|
| Toxicity/Toxicokinetics |
The toxicity profile of 3-Pyridinemethanol has been evaluated in the context of its use as a vasodilator and cholesterol-lowering agent. The compound is an alcohol analog of nicotinic acid. As a vasodilator, it causes flushing as a common side effect. Proper handling procedures including use of personal protective equipment are recommended when working with pure compound. The compound is not approved for human therapeutic use and is intended for research purposes only. Long-term toxicity studies would be needed to fully establish its safety profile for pharmaceutical applications. The compound's vasodilatory effects should be carefully evaluated in safety studies.
|
| References |
[1]. Heiberg A. Nikotinyl-alkohol som kolesterolsenkende medikament [Nicotinyl alcohol as a cholesterol-lowering agent]. Nord Med. 1969;81(22):698-700.
[2]. Gargaun S, et al. A novel method aimed at counteracting the side effects caused by prostaglandin e2 deficiency during non-steroidal anti-inflammatory drug therapy. Antiinflamm Antiallergy Agents Med Chem. 2014;13(2):121-127. |
| Additional Infomation |
3-Pyridinemethanol is a pyridine compound with a hydroxymethyl group substituted at the 3-position of pyridine. It has dual effects of vasodilation and lipid-lowering. It belongs to the pyridine class of compounds and is also an aromatic primary alcohol. 3-Pyridinemethanol has been reported to be found in saffron (Crocus sativus) and tobacco (Nicotiana tabacum), and relevant data exist. It is an alcohol analog of nicotinic acid, a vasodilator that acts directly on peripheral blood vessels, causing flushing and potentially lowering blood pressure. It is used to treat vasospasm and gangrene.
3-Pyridinemethanol (CAS# 100-55-0) is also known as Nicotinyl alcohol, Pyridine-3-carbinol, and Roniacol. It has the molecular formula C6H7NO and a molecular weight of 109.13. The compound is a pyridine derivative that acts as a cholesterol-lowering agent. It can be selectively oxidized to vitamin B3. The compound is a direct-acting peripheral vasodilator that causes flushing and may decrease blood pressure. It has a role as a vasodilator agent and an antilipemic drug. The compound has been reported in Crocus sativus and Nicotiana tabacum. It has a purity of 99.53% and is intended for research use only. |
| Molecular Formula |
C6H7NO
|
|---|---|
| Molecular Weight |
109.13
|
| Exact Mass |
109.052
|
| CAS # |
100-55-0
|
| Related CAS # |
100-55-0(FREE BASE)
|
| PubChem CID |
7510
|
| Appearance |
Light yellow to light brown liquid（Density：1.124 g/cm3）
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
266.0±0.0 °C at 760 mmHg
|
| Melting Point |
-7 °C
|
| Flash Point |
97.5±20.4 °C
|
| Vapour Pressure |
0.0±0.5 mmHg at 25°C
|
| Index of Refraction |
1.551
|
| LogP |
-0.46
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
8
|
| Complexity |
65.5
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
OCC1=CC=CN=C1
|
| InChi Key |
MVQVNTPHUGQQHK-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C6H7NO/c8-5-6-2-1-3-7-4-6/h1-4,8H,5H2
|
| Chemical Name |
pyridin-3-ylmethanol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (916.34 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (22.91 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (22.91 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (22.91 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 9.1634 mL | 45.8169 mL | 91.6338 mL | |
| 5 mM | 1.8327 mL | 9.1634 mL | 18.3268 mL | |
| 10 mM | 0.9163 mL | 4.5817 mL | 9.1634 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
